All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. All P values are two-sided, with a P value of less than 0.05 used to indicate statistical significance, without adjustment for multiple comparisons.The primary outcome was vomiting during oral rehydration in the emergency department after the receipt of ondansetron or placebo. Usual Pediatric Dose for Nausea/Vomiting - Chemotherapy Induced. The parents of two of these children refused to allow a second dose to be given; the remaining child was given a second dose, which was tolerated.Of the 107 children in each group whose data were analyzed, 15 who received ondansetron vomited while receiving oral-rehydration therapy, as compared with 37 who received placebo (14 percent vs. 35 percent, P<0.001) (Fifteen children in the ondansetron group (14 percent) and 33 in the placebo group (31 percent) received intravenous rehydration (P=0.003). Please confirm that you would like to log out of Medscape. A mixed-effects linear regression model was used for the outcomes of volume of oral-rehydration fluid and volume of intravenous fluid administered, with the physician as the random effect. Our study was powered, on the basis of previous data, to detect a reduction from 15 percent to 3 percent.The total cost of the ondansetron used in this study, based on actual costs of $35.75 per 4-mg orally disintegrating tablet at Children's Memorial Hospital, would have been $3,825.

2002 Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Information, resources, and support needed to approach rotations - and life as a resident.Valuable tools for building a rewarding career in health care.Information and tools for librarians about site license offerings.The authorized source of trusted medical research and education for the Chinese-language medical community.The most trusted, influential source of new medical knowledge and clinical best practices in the world.Oral Ondansetron for Gastroenteritis in a Pediatric Emergency Department Dose: 8 mg PO q4h x3 doses, then 8 mg PO q8h until 1-2 days after chemo complete; Start: 30min before chemo nausea/vomiting prevention, postop [1 mo-12 yo and 40 kg] Dose: 0.1 mg/kg/dose IV x1; Max: 4 mg; Info: give immed. Ondansetron/Zofran ODT Oral Tab Orally Dis: 4mg, 8mg Zuplenz Oral Film: 4mg, 8mg .

/viewarticle/937227

Table 1: Adult Recommended Dosage Regimen for Prevention of Nausea and VomitingFor single high-dose fraction radiotherapy to the abdomen:For daily fractionated radiotherapy to the abdomen:Table 2: Pediatric Recommended Dosage Regimen for Prevention of Nausea and Vomiting[see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]We comply with the HONcode standard for trustworthy health information - A data and safety monitoring board reviewed adverse outcomes in a blinded fashion.We estimated that the enrollment of 214 children would provide the study with a statistical power of 90 percent to detect a change from 35 percent in the control group to 15 percent in the treatment group in the proportion of children who vomited during oral rehydration, given a two-sided type I error of 0.05.

Children who received ondansetron had more episodes of diarrhea while undergoing oral rehydration than those who received placebo (1.4 vs. 0.5, P<0.001), even after adjustment for the number of episodes occurring before arrival. As compared with children who received placebo, children who received ondansetron had fewer episodes of vomiting, greater oral intake of fluids, and a shorter stay in the emergency department.To prevent vomiting in 1 child, 5 children had to receive ondansetron (95 percent confidence interval, 3.2 to 10.6); to prevent 1 child from having to be treated by intravenous rehydration, 6 had to receive ondansetron (95 percent confidence interval, 3.6 to 17.0). Among the 92 children in the ondansetron group and the 70 children in the placebo group who did not vomit, intravenous hydration was less common in the ondansetron group (5 percent vs. 17 percent; P=0.01; relative risk, 0.32; 95 percent confidence interval, 0.13 to 0.77).